Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ platform for recombinant viral vector manufacturing.

Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective...

PathoQuest Secures 8 Million Euros in New Financing

Paris, FRANCE -- (BUSINESS WIRE) -- September 5, 2019 -- PathoQuest, a genomic expert company dedicated to the microbiology testing market and a leader in clinical diagnostics and biologics testing applications, today announces the closing of an 8M euros financing...

PathoQuest announces enrollment of first patient in IDENTIFY, a prospective clinical study assessing the medico-economic benefit of iDTECT™ Blood for the diagnosis of bloodstream infection in immunocompromised patients

Pour la version en français de ce communiqué de presse : cliquez ici PARIS, FRANCE, May 22, 2018 – PathoQuest, a genomic expert for biologics testing and a leader in improving pathogen identification in clinical biological samples, today announced the...